

TAFI Deficient Plasma

Product No. ADG216

Lot XXXXXX

Description

Thrombin-Activatable Fibrinolysis Inhibitor (TAFI) Deficient Plasma is manufactured from pooled normal human plasma depleted of TAFI using antibodies directed to TAFI. Only the highest quality citrated plasma is used as starting material.

Specification

Activity assay	Lot XXXXXX
PT (Stago Neoplastine C1+)	XXX sec
APTT (Actin FSL)	XXX sec
Fibrinogen (clottable)	XXX G/L
TAFI (antigen) by ELISA	< XXX U/ml

Application

For research assays of TAFI antigen and functionality as a negative control and for dilution of standards and test samples.

Distributed by:

LOXO GMBH

IMMUNOLOGIE • MOLEKULARBIOLOGIE
BIOCHEMIE • PRODUKTE UND SYSTEME

Gerhart-Hauptmann-Str. 48
69221 Dossenheim

Tel +49 6221 868023
Fax +49 6221 8680255

www.loxo.de - info@loxode

Warning

The plasma is prepared from screened normal citrated human plasma that have been tested and found negative for HIV and Hepatitis by FDA-approved methods.

As no known test method can provide complete assurance that products derived from human blood will not transmit HBsAg, HCV, HIV-1, HIV-2 or other blood-borne pathogens, this reagent should be handled as recommended for any potentially infectious human specimen.

Presentation

Set of 5 clear, screw-capped vials each containing 1 mL of lyophilized plasma. The plasma contains 50mM HEPES and stabilizers.

Reconstitution and Stability

One vial of lyophilized product is reconstituted by addition of 1 mL of distilled water, employing gentle agitation for 15 minutes, at room temperature. Stability after reconstitution is 4 hours at ambient (18° -25°C), or 30 days at -20 °C.

Storage

Prior to reconstitution, dried plasma should be stored at 2° - 8°C.

Hinweis/Note:

Der Packungsbeileger dient nur als erste Information. Der relevante Packungsbeileger liegt der Ware bei.

The datasheet is for information purposes only. The current datasheet will be enclosed with product shipment.

For research use only!

ADG216©08072019_Lot